120758-24-9

Usage

Molecular weight

272.36 g/mol

Appearance

Clear to slightly yellow liquid

Solubility

Soluble in water and most organic solvents

Boiling point

121-123°C

Melting point

Not applicable (decomposes)

Functional groups

Phenyl, methoxy, and benzenesulfonate groups

Uses

As a surfactant, emulsifier, and stabilizer in various industrial and household products, including personal care products (e.g. shampoos, conditioners, and body washes) and cleaning products.

Upstream product

• 100-52-7 benzaldehyde 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 772-01-0 2-phenyl-1,3-dioxane 
• 4799-68-2 3-benzyloxypropan-1-ol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 185854-00-6 N-(3-Benzyloxypropyl)-2,2,2-trifluoroacetamide 
• 182919-59-1 O,O',O'',O'''-tetrakis(3-benzyloxypropyl)pentaerythrol 
• 635677-62-2 dibenzyl hexapropyleneglycol 
• 635677-60-0 1-benzyloxy-3-(3-benzyloxy-propoxy)propane 
• 635677-61-1 dibenzyl tetrapropyleneglycol 
• 744262-47-3 9-(3-benzyloxypropyl)adenine 
• 5375-00-8 3-benzyloxypropyl iodide 
• 100571-53-7 6-(benzyloxy)hex-2-yn-1-ol 
• 794513-19-2 (Z)-6-(benzyloxy)hex-2-en-1-ol 
• 794512-99-5 [(2R,3S)-3-(3-Benzyloxy-propyl)-oxiranyl]-methanol 
• 794513-18-1 (6-benzyloxy-hex-2-ynyloxy)-tert-butyl-diphenyl-silane 
• 170788-63-3 2,2-dimethyl-4-[N-(3-benzyloxypropyl)-N-(β-trimethylsilylethanesulfonyl)aminomethyl]-1,3-dioxolane 
• 1325724-17-1 dibenzyl-[2-(3-benzyloxypropoxy)ethyl]amine 
• 1423218-40-9 tert-butyl (2R)-(1-(1-(3-benzyloxypropyl)-7-cyanoindolin-5-yl)propane-2-yl)-N-(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)carbamate 

Relevant academic research and scientific papers

Employing in vitro metabolism to guide design of F-labelled PET probes of novel α-synuclein binding bifunctional compounds

A challenge in the development of novel 18F-labelled positron emission tomography (PET) imaging probes is identification of metabolically stable sites to incorporate the 18F radioisotope. Metabolic loss of 18F from PET probes in vivo can lead to misleading biodistribution data as displaced 18F can accumulate in various tissues. In this study we report on in vitro hepatic microsomal metabolism of novel caffeine containing bifunctional compounds (C8-6-I, C8-6-N, C8-6-C8) that can prevent in vitro aggregation of α-synuclein, which is associated with the pathophysiology of Parkinson’s disease. The metabolic profile obtained guided us to synthesize stable isotope 19F-labelled analogues in which the fluorine was introduced at the metabolically stable N7 of the caffeine moiety. An in vitro hepatic microsomal metabolism study of the 19F-labelled analogues resulted in similar metabolites to the unlabelled compounds and demonstrated that the fluorine was metabolically stable, suggesting that these analogues are appropriate PET imaging probes. This straightforward in vitro strategy is valuable for avoiding costly stability failures when designing radiolabelled compounds for PET imaging.

Nickel-Catalyzed Decarboxylative Coupling of Redox-Active Esters with Aliphatic Aldehydes

The addition of alkyl fragments to aliphatic aldehydes is a highly desirable transformation for fragment couplings, yet existing methods come with operational challenges related to the basicity and instability of the nucleophilic reagents commonly employed. We report herein that nickel catalysis using a readily available bioxazoline (BiOx) ligand can catalyze the reductive coupling of redox-active esters with aliphatic aldehydes using zinc metal as the reducing agent to deliver silyl-protected secondary alcohols. This protocol is operationally simple, proceeds under mild conditions, and tolerates a variety of functional groups. Initial mechanistic studies suggest a radical chain pathway. Additionally, alkyl tosylates and epoxides are suitable alkyl precursors to this transformation providing a versatile suite of catalytic reactions for the functionalization of aliphatic aldehydes.

INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION

Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Compounds and Their Use in Treating Cancer

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Synthesis of Silodosin by Copper-Catalysed C-C Arylation

The synthesis of silodosin, an antidysuria drug, has been accomplished starting from commercially available indoline. The synthetic strategy is based on CuI-catalysed C-C arylation, regioselective cyanation, and diastereoselective reductive amination. The enantiopure compound was obtained by selective crystallisation of a diasteroisomeric mixture.

METHOD OF PREPARING ADRENERGIC ANTAGONIST

PROBLEM TO BE SOLVED: To provide a method of preparing a selective adrenergic antagonist for an α-1A-adrenergic receptor and a useful intermediate thereof. SOLUTION: This invention provides an advantageous production method of a novel intermediate particularly fitted for production on an industrial scale, regarding the production of a pharmaceutical compound represented by formula (I), silodosin: 1-(3-hydroxypropyl)-5-[(2R)-({2-[2-[2-(2,2,2-trifluoroethoxy) phenoxy]ethyl}amino) propyl]indoline-7-carboxamide, or salt thereof. COPYRIGHT: (C)2015,JPOandINPIT

Polyaniline copolymers with solvent-mimic side chains

We investigated new polyaniline copolymers with solvent-mimic side chains for enhanced processability in various solvents. The solvent-mimic side chains, benzyloxypropoxy (BOP), phenoxybutoxy (POB), and dihydroxypropoxy (DHP), were introduced into copolym

Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof

Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.